Telix Pharmaceuticals

Clinical Trial · NCT07931261

[18F]FET PET for Differentiating Tumor Progression vs Treatment-Related Changes in Brain Metastases

Overview

This Phase 3 study will evaluate whether \[18F\]Floretyrosine (\[18F\]FET) PET imaging can help distinguish active brain tumor growth from treatment-related changes in patients with brain metastases who have unclear MRI findings after treatment. The study has two parts. Part 1 will identify the lowest effective dose of \[18F\]FET PET that provides reliable imaging results. Part 2 will evaluate the accuracy of \[18F\]FET PET, using the optimized dose, for distinguishing tumor progression from treatment-related changes. Study results will be compared with information from follow-up imaging, clinical assessments, and, when available, tissue samples obtained during routine clinical care. The goal is to determine whether \[18F\]FET PET can improve diagnostic accuracy and support clinical decision-making for patients with brain metastases.

Phase

Phase 3

ClinicalTrials.gov

NCT07931261

Study contact

Sahar Khan, Clinical Project Manager, MBA, MS

Sapna Shah, Senior Director, Clinical Operations, MD

Eligibility

Inclusion

  • Prior diagnosis of brain metastases from a histologically confirmed solid tumor.
  • Life expectancy of at least 3 months.
  • At least one measurable intracranial lesion (≥10 mm longest diameter and/or ≥5 mm short axis) identified on MRI and assessed according to RANO-BM criteria.
  • Planned standard-of-care management including biopsy/neurosurgical intervention and/or clinical follow-up MRI within 2 to 3 months after Day 1.
  • Target lesion considered equivocal for tumor progression versus treatment-related changes on MRI within 1 month prior to Day 1.
  • ECOG Performance Status 0-2.
  • Prior receipt of CNS-directed therapy for brain metastases within 12 months before Day 1.

Exclusion

  • Any condition that, in the investigator's opinion, would make the participant unsuitable for the study.
  • Absence of at least one measurable intracranial lesion.
  • Exposure to a diagnostic or therapeutic radiopharmaceutical within protocol-specified washout periods.
  • Pregnant or breastfeeding women.
  • Exposure to another investigational agent within 30 days prior to Day 1 or participation in a conflicting clinical study.
  • Known hypersensitivity to \[18F\]FET or tyrosine derivatives.
  • Serious non-malignant disease that may interfere with study objectives, safety, or compliance.
  • Inability to undergo required imaging procedures or comply with study requirements.
  • Contraindication to PET, CT, or MRI procedures.
  • Ongoing Grade 3 toxicity from previous therapies.
  • Whole brain radiotherapy or stereotactic radiosurgery within 2 months prior to Day 1.

Patient Education

Patient education not yet provided.

Publications

Publications not yet provided.

Locations

Loading…